Stockscreener 앱 받기
22.49
3.31%
-0.77
시장 영업 전:
22.28
-0.21
-0.93%
전일 마감가:
$23.26
열려 있는:
$23.31
하루 거래량:
596.80K
Relative Volume:
0.93
시가총액:
$1.65B
수익:
$81.26M
순이익/손실:
$-102.66M
주가수익비율:
-16.44
EPS:
-1.3678
순현금흐름:
$-77.62M
1주 성능:
-3.31%
1개월 성능:
-6.02%
6개월 성능:
-13.00%
1년 성능:
+77.79%
1일 변동 폭
$22.14
$23.42
1주일 범위
$22.14
$23.57
52주 변동 폭
$11.51
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
22.49 | 1.71B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Citizens reiterates Zymeworks stock rating on ADC pipeline progress By Investing.com - Investing.com Canada
Zymeworks (ZYME) Unveils Promising Phase 1 Data for ZW191 in Ova - GuruFocus
Zymeworks reports phase 1 trial results for ovarian cancer drug By Investing.com - Investing.com South Africa
Zymeworks Inc. Reports Promising Phase 1 Results for ZW191 in Platinum-Resistant Ovarian Cancer Patients - Quiver Quantitative
Ovarian cancer study: 78.6% response in one group on Zymeworks' ZW191 - Stock Titan
Zymeworks Inc. (ZYME) reports Q1 loss, misses revenue estimates - MSN
ZYME Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Continues R&D InvestmentQuarterly Financial Update - newsline.com
Truist assumes Zymeworks stock coverage with buy rating on royalty platform - Investing.com UK
Truist assumes Zymeworks stock coverage with buy rating on royalty platform By Investing.com - Investing.com India
Zymeworks stock drops 4.22% as Zymeworks Inc posts National Cancer Survivors Day tribute - Traders Union
Is Zymeworks’ ADC Progress And Buyback Plan Reframing The Investment Case For ZYME? - Sahm
A Look At Zymeworks (ZYME) Valuation After Recent Clinical And Regulatory Milestones - Sahm
Zymeworks stock price target maintained at $46 by H.C. Wainwright - Investing.com UK
Truist Securities initiates coverage of Zymeworks (ZYME) with buy recommendation - MSN
ZYME Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Zymeworks Inc stock (US98986T1088): upcoming Jefferies conference appearance in focus - AD HOC NEWS
ZYME News | ZYMEWORKS INC (NASDAQ:ZYME) - ChartMill
Zymeworks Inc stock (US98985W1080): investor focus on AACR data and sector backdrop - AD HOC NEWS
Zymeworks (ZYME) Shares Slip 2.4%, Testing Support Near $23.55Monthly Profile - thelegaladvocate.com
Zymeworks Inc. (ZYME) Faces Selling Pressure as Shares Dip 2.40% — Key Levels in FocusPut Call Ratio - thelegaladvocate.com
Zymeworks Inc. (ZYME) Edges Higher as Support Holds SteadyTWAP Entry - The Legal Advocate
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? - MSN
Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Zymeworks Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks Inc. (ZYME) - Minichart
Breakeven Is Near for Zymeworks Inc. (NASDAQ:ZYME) - Moomoo
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality (ZYME) - Seeking Alpha
Zymeworks authorizes fresh $125M share buyback - MSN
Zymeworks Inc stock (US98985W1080): buyback plan and insider equity awards draw fresh attention - AD HOC NEWS
Zymeworks grants RSUs and options to EVP | ZYME Insider Trading - Stock Titan
Zymeworks (ZYME) EVP files Form 3 reporting no share ownership - Stock Titan
Rubric Capital, David Rosen disclose 9.49% stake in Zymeworks (ZYME) - Stock Titan
Vanguard Group Inc. Increases Position in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity - TipRanks
Zymeworks authorizes $125 million share buyback program - Investing.com UK
Zymeworks authorizes $125 million share buyback program By Investing.com - Investing.com South Africa
Zymeworks Inc. announces an Equity Buyback for $125 million worth of its shares. - marketscreener.com
Zymeworks (NASDAQ: ZYME) launches $125M stock buyback and outlines runway - Stock Titan
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock - The Manila Times
Biotech Zymeworks lines up $125M for 2026 buyback program - Stock Titan
Zymeworks Inc.'s Equity Buyback announced on November 16, 2025, has expired with 4,197,553 shares, representing 5.62% for $102.3 million. - marketscreener.com
Zymeworks to present at three major investor conferences in May and June 2026 - Pluang
Zymeworks Announces Participation in Upcoming Investor Conferences - Koreabizwire
About Us | Cabling Installation & MaintenanceZymeworks Announces Participation in Upcoming Investor Conferences - FinancialContent
Zymeworks Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-05-12 - Seeking Alpha
Earnings call transcript: Zymeworks reports Q1 2026 revenue drop, outlines strategic advancements - Investing.com India
Earnings call transcript: Zymeworks reports Q1 2026 revenue drop, outlines strategic advancements By Investing.com - Investing.com Australia
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):